In Brief: Wyeth-Ayerst Lodine XL
Wyeth-Ayerst Lodine XL: Extended-release etodolac approved Oct. 25 for treatment of signs and symptoms of rheumatoid and osteoarthritis. The once-daily formulation of the non-steroidal anti-inflammatory became "approvable" on July 3; the NDA was filed in March 1995. Lodine XL will available in 400 mg and 600 mg tablets at an average wholesale price of $100 and $190, respectively, for 100-count bottles. The company says the price represents a 10% reduction in cost compared to regular Lodine therapy...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth